• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1.

作者信息

Yang Ge, Li Ziyue, Mohammed Irfan, Zhao Liping, Wei Wei, Xiao Haihua, Guo Weisheng, Zhao Yongxiang, Qu Feng, Huang Yuanyu

机构信息

School of Life Science; Advanced Research Institute of Multidisciplinary Science; Institute of Engineering Medicine; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, China.

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China.

出版信息

Signal Transduct Target Ther. 2021 Jun 10;6(1):227. doi: 10.1038/s41392-021-00649-6.

DOI:10.1038/s41392-021-00649-6
PMID:34112756
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8190169/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab6e/8192746/2db04e52885b/41392_2021_649_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab6e/8192746/2db04e52885b/41392_2021_649_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab6e/8192746/2db04e52885b/41392_2021_649_Fig1_HTML.jpg

相似文献

1
Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1.通过阻断刺突蛋白1的RBD结构域鉴定具有高中和活性的抗SARS-CoV-2适配体。
Signal Transduct Target Ther. 2021 Jun 10;6(1):227. doi: 10.1038/s41392-021-00649-6.
2
Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.利用 Spike 的适体功能化脂质纳米粒特异性递送 RNAi 靶向 SARS-CoV-2：临床病例研究中的强力抗新冠病毒药物。
Chem Biol Drug Des. 2022 Feb;99(2):233-246. doi: 10.1111/cbdd.13978. Epub 2021 Nov 24.
3
A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism*.一种通过非 RBD 依赖机制抑制假病毒感染的 SARS-CoV-2 刺突结合 DNA 适体*。
Angew Chem Int Ed Engl. 2021 Apr 26;60(18):10279-10285. doi: 10.1002/anie.202100316. Epub 2021 Mar 23.
4
Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.适体阻断策略抑制 SARS-CoV-2 病毒感染。
Angew Chem Int Ed Engl. 2021 Apr 26;60(18):10266-10272. doi: 10.1002/anie.202100225. Epub 2021 Mar 10.
5
Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.中和适体阻断 S/RBD-ACE2 相互作用并防止宿主细胞感染。
Angew Chem Int Ed Engl. 2021 Apr 26;60(18):10273-10278. doi: 10.1002/anie.202100345. Epub 2021 Mar 22.
6
Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.异核酸（XNA）2'-氟阿拉伯糖核酸（FANA）适体与 SARS-CoV-2 S 蛋白受体结合域结合，阻断 ACE2 结合。
Viruses. 2021 Oct 2;13(10):1983. doi: 10.3390/v13101983.
7
Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2.SARS-CoV 核衣壳蛋白特异性核酶抗性 RNA 适体的再利用用于治疗 SARS-CoV-2。
Infect Genet Evol. 2020 Nov;85:104497. doi: 10.1016/j.meegid.2020.104497. Epub 2020 Aug 11.
8
Molecular Mechanism of Interaction between DNA Aptamer and Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus 2 Variants Revealed by Steered Molecular Dynamics Simulations.基于定向分子动力学模拟揭示的 DNA 适体与严重急性呼吸综合征冠状病毒 2 变异株受体结合域相互作用的分子机制。
Molecules. 2024 May 9;29(10):2215. doi: 10.3390/molecules29102215.
9
Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.通过药物文库的体外筛选鉴定 SARS-CoV-2 受体结合抑制剂。
Molecules. 2021 May 27;26(11):3213. doi: 10.3390/molecules26113213.
10
The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms.肝素与刺突糖蛋白结合通过三种机制抑制 SARS-CoV-2 感染。
J Biol Chem. 2022 Feb;298(2):101507. doi: 10.1016/j.jbc.2021.101507. Epub 2021 Dec 18.

引用本文的文献

1
Development of Novel ssDNA Aptamers for Detection of Receptor-Binding Domain of SARS-COV‑2.用于检测新型冠状病毒受体结合域的新型单链DNA适配体的开发
ACS Omega. 2025 Jun 3;10(23):23981-23992. doi: 10.1021/acsomega.4c03580. eCollection 2025 Jun 17.
2
[Advances in exosome-targeting aptamer-screening techniques].[外泌体靶向适配体筛选技术的进展]
Se Pu. 2025 May;43(5):424-433. doi: 10.3724/SP.J.1123.2024.10029.
3
Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的复制特征以及适配体靶向刺突蛋白（S蛋白）以阻断病毒进入的优势

本文引用的文献

1
Nucleic Acids Analysis.核酸分析
Sci China Chem. 2021;64(2):171-203. doi: 10.1007/s11426-020-9864-7. Epub 2020 Dec 2.
2
Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape.用于 SARS-CoV-2 检测的诊断方法：美国食品药品监督管理局紧急使用授权 COVID-19 检测全景的综合回顾。
Biosens Bioelectron. 2020 Oct 1;165:112454. doi: 10.1016/j.bios.2020.112454. Epub 2020 Jul 18.
3
COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).
ACS Omega. 2025 Apr 21;10(16):15840-15851. doi: 10.1021/acsomega.4c10933. eCollection 2025 Apr 29.
4
Aptamer-engaged nanotherapeutics against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的适配体结合纳米疗法。
Discov Nano. 2025 Apr 27;20(1):71. doi: 10.1186/s11671-025-04245-3.
5
Quantitative Characterization of Partitioning Stringency in SELEX.SELEX中分区严格性的定量表征
JACS Au. 2024 Dec 9;4(12):4910-4920. doi: 10.1021/jacsau.4c00890. eCollection 2024 Dec 23.
6
Dimeric DNA Aptamers for the Spike Protein of SARS-CoV-2 Derived from a Structured Library with Dual Random Domains.源自具有双随机结构域的结构化文库的新冠病毒刺突蛋白二聚体DNA适配体
Small Methods. 2024 Dec 20:e2401600. doi: 10.1002/smtd.202401600.
7
Aptamer and DNAzyme Based Colorimetric Biosensors for Pathogen Detection.基于适配体和脱氧核酶的比色生物传感器用于病原体检测
Angew Chem Int Ed Engl. 2025 Jan 21;64(4):e202418725. doi: 10.1002/anie.202418725. Epub 2024 Nov 25.
8
Aptamer-decorated nanocarriers for viral adsorption: A special look at COVID-19.用于病毒吸附的适配体修饰纳米载体：对新冠病毒的特别关注
Mol Ther Nucleic Acids. 2024 Aug 15;35(3):102310. doi: 10.1016/j.omtn.2024.102310. eCollection 2024 Sep 10.
9
A Multi-Faceted Binding Assessment of Aptamers Targeting the SARS-CoV-2 Spike Protein.针对 SARS-CoV-2 刺突蛋白的适体的多方面结合评估。
Int J Mol Sci. 2024 Apr 24;25(9):4642. doi: 10.3390/ijms25094642.
10
A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response.一种新的 DNA 适体可与 SARS-CoV-2 刺突蛋白结合并减少促炎反应。
Sci Rep. 2024 Mar 29;14(1):7516. doi: 10.1038/s41598-024-58315-0.
COVID-19 治疗：接近治愈？新型冠状病毒（SARS-CoV-2）药物治疗的快速综述。
Int J Antimicrob Agents. 2020 Aug;56(2):106080. doi: 10.1016/j.ijantimicag.2020.106080. Epub 2020 Jul 4.
4
Therapeutic siRNA: state of the art.治疗性 siRNA：最新进展。
Signal Transduct Target Ther. 2020 Jun 19;5(1):101. doi: 10.1038/s41392-020-0207-x.
5
Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.靶向 SARS-CoV-2 刺突糖蛋白受体结合域的适体的发现。
Anal Chem. 2020 Jul 21;92(14):9895-9900. doi: 10.1021/acs.analchem.0c01394. Epub 2020 Jul 2.